Trends in Fluoroquinolone Resistance of Bacteria Isolated from Canine Urinary Tracts

Fluoroquinolone (FQ) antimicrobial agents are used extensively in human and veterinary medicine. Widespread use of any antimicrobial agent can apply selective pressure on populations of bacteria, which may result in an increase in the prevalence of antimicrobial-resistant isolates. Antimicrobial-susceptibility data on bacteria isolated from the canine urinary tract by the University of Missouri-Columbia Veterinary Medical Diagnostic Laboratory, Columbia, MO, were used to determine whether there has been an increase in the prevalence of FQ-resistant bacteria over time. Between January 1992 and December 2001, minimum inhibitory concentrations of either ciprofloxacin (1992–1998) or enrofloxacin (1998–2001) were determined for 1,478 bacterial isolates from the canine urinary tract. The predominant bacterial species isolated were Escherichia coli (547 isolates), Proteus mirabilis (156), and Staphylococcus intermedius (147). In all, there were 13 bacterial species with more than 25 isolates each. A significant increase in the overall proportion of resistant bacterial isolates was documented from 1992 to 2001 (Cochran-Armitage test for trend, P < 0.0001). The same increase in resistant isolates was documented when either ciprofloxacin or enrofloxacin was analyzed separately (P < 0.0001 and P < 0.0002, respectively). No difference was detected in rates of bacterial FQ resistance with regard to the sex of the dog from which the bacteria were isolated. The frequency with which some bacterial species were isolated differed with the sex of the infected dog. Proteus mirabilis was found more often in females (P < 0.0001), whereas beta hemolytic Streptococcus spp., were found more often in males (P = 0.0003). Although the overall efficacy of FQ antimicrobials remained high with greater than 80% of isolates being susceptible, the data demonstrated an increase in the proportion of resistant bacteria isolated from the urinary tract of the dog.

[1]  D. Livermore,et al.  Trends in Fluoroquinolone (Ciprofloxacin) Resistance in Enterobacteriaceae from Bacteremias, England and Wales, 1990–1999 , 2002, Emerging infectious diseases.

[2]  R. Singer,et al.  Enrofloxacin resistance in Escherichia coli isolated from dogs with urinary tract infections. , 2002, Journal of the American Veterinary Medical Association.

[3]  C. Franti,et al.  Interrelations of organism prevalence, specimen collection method, and host age, sex, and breed among 8,354 canine urinary tract infections (1969-1995). , 2001, Journal of veterinary internal medicine.

[4]  I. Kakoma,et al.  Nonenteric Escherichia coli isolates from dogs: 674 cases (1990-1998). , 2001, Journal of the American Veterinary Medical Association.

[5]  N. Nagelkerke,et al.  Increasing resistance to fluoroquinolones in escherichia coli from urinary tract infections in the netherlands. , 2000, The Journal of antimicrobial chemotherapy.

[6]  D. Polzin Therapy of Canine and Feline Urinary Tract Infections with Enrofloxacin , 1999 .

[7]  B. Malorny,et al.  Incidence of Quinolone Resistance Over the Period 1986 to 1998 in Veterinary Salmonella Isolates from Germany , 1999, Antimicrobial Agents and Chemotherapy.

[8]  A. Brisabois,et al.  Comparative Studies of Mutations in Animal Isolates and Experimental In Vitro- and In Vivo-Selected Mutants ofSalmonella spp. Suggest a Counterselection of Highly Fluoroquinolone-Resistant Strains in the Field , 1999, Antimicrobial Agents and Chemotherapy.

[9]  A. J. van der Ven,et al.  Antimicrobial resistance patterns in urinary isolates from nursing home residents. Fifteen years of data reviewed. , 1999, The Journal of antimicrobial chemotherapy.

[10]  C. J. Thomson The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective. , 1999, The Journal of antimicrobial chemotherapy.

[11]  L. Piddock Fluoroquinolone resistance , 1998, BMJ.

[12]  M. Louie,et al.  Antimicrobial susceptibilities of blood culture isolates obtained before and after the introduction of ciprofloxacin. , 1997, The Journal of antimicrobial chemotherapy.

[13]  S. A. Brown Fluoroquinolones in animal health. , 1996, Journal of veterinary pharmacology and therapeutics.

[14]  S. Shin,et al.  Evaluation of a Commercial Automated System and Software for the Identification of Veterinary Bacterial Isolates , 1995, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

[15]  K. Küng,et al.  Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs. , 1993, Journal of veterinary pharmacology and therapeutics.

[16]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[17]  L. Piddock,et al.  Quinolone accumulation by Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. , 1999, The Journal of antimicrobial chemotherapy.

[18]  R. Walker,et al.  Decrease in antibiotic susceptibility or increase in resistance? , 1998, The Journal of antimicrobial chemotherapy.

[19]  J. Waitz Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .

[20]  H. Neu Bacterial resistance to fluoroquinolones. , 1988, Reviews of infectious diseases.